Search details
1.
Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology?
Therapie
; 71(6): 625-632, 2016 Dec.
Article
in English
| MEDLINE | ID: mdl-27639631
2.
Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.
Value Health
; 17(5): 634-41, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-25128058
3.
Endpoints for relative effectiveness assessment (REA) of pharmaceuticals.
Int J Technol Assess Health Care
; 30(5): 508-13, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25747560
4.
An Inclusive Civil Society Dialogue for Successful Implementation of the EU HTA Regulation: Call to Action to Ensure Appropriate Involvement of Stakeholders and Collaborators.
J Mark Access Health Policy
; 12(1): 21-34, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38544972
5.
The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy's multi-stakeholder pre-convention questionnaire.
J Mark Access Health Policy
; 11(1): 2217543, 2023.
Article
in English
| MEDLINE | ID: mdl-37284060
6.
Pre-market clinical evaluations of innovative high-risk medical devices in Europe.
Int J Technol Assess Health Care
; 28(3): 278-84, 2012 Jul.
Article
in English
| MEDLINE | ID: mdl-22980705
7.
Shaping a research agenda to ensure a successful European health technology assessment: insights generated during the inaugural convention of the European access academy.
Health Econ Rev
; 12(1): 54, 2022 Nov 05.
Article
in English
| MEDLINE | ID: mdl-36333433
8.
[Not Available]. / Survie sans progression, survie globale et qualité de vie : quel intérêt au plan médicoéconomique en oncologie ?
Therapie
; 71(1): 59-67, 2016 Feb.
Article
in French
| MEDLINE | ID: mdl-27080631
9.
Vaccine market access pathways in the EU27 and the United Kingdomâ¯-â¯analysis and recommendations for improvements.
Vaccine
; 39(39): 5706-5718, 2021 09 15.
Article
in English
| MEDLINE | ID: mdl-34404557
10.
Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients.
Dermatol Ther (Heidelb)
; 11(5): 1791-1804, 2021 Oct.
Article
in English
| MEDLINE | ID: mdl-34510404
11.
[Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique]. / Recommandations d'utilisation des biosimilaires de l'érythropoïétine (EPO). Propositions de la Société de néphrologie, de la Société francophone de dialyse et de la Société de néphrologie pédiatrique.
Nephrol Ther
; 5(1): 61-6, 2009 Feb.
Article
in French
| MEDLINE | ID: mdl-19084489
12.
Similar biological medicinal products containing recombinant human growth hormone: European regulation.
Horm Res
; 69(1): 14-21, 2008.
Article
in English
| MEDLINE | ID: mdl-18059081
13.
Challenges for Relative Effectiveness Assessment and Early Access of Cancer Immunotherapies in Europe.
Front Med (Lausanne)
; 3: 56, 2016.
Article
in English
| MEDLINE | ID: mdl-27896268
14.
European collaboration on relative effectiveness assessments: What is needed to be successful?
Health Policy
; 119(5): 569-76, 2015 May.
Article
in English
| MEDLINE | ID: mdl-25703539
15.
Efficacy of imiquimod on external anogenital warts in HIV-infected patients previously treated by highly active antiretroviral therapy.
AIDS
; 16(10): 1438-40, 2002 Jul 05.
Article
in English
| MEDLINE | ID: mdl-12131230
16.
Tick removal with liquid nitrogen.
JAMA Dermatol
; 149(5): 633, 2013 May.
Article
in English
| MEDLINE | ID: mdl-23677109
17.
Reimbursement of dressings: a WUWHS statement.
Int Wound J
; 3(4): 296-301, 2006 Dec.
Article
in English
| MEDLINE | ID: mdl-17199765
Results
1 -
17
de 17
1
Next >
>>